Teva Pharma Posts Profit In Q2, Adj. EPS Beats Market, While Revenues Miss; Lifts FY25 Earnings View
I'm PortAI, I can summarize articles.
Teva Pharmaceutical Industries Ltd (TEVA) reported a profit in Q2, reversing last year's loss, with adjusted earnings of $0.66 per share beating estimates. However, revenues of $4.176 billion fell short of the expected $4.27 billion. The company raised its FY25 adjusted earnings outlook to $2.50-$2.65 per share and maintained revenue expectations of $16.8-$17.2 billion. Teva aims for a 30% operating profit margin by 2027 as part of its growth strategy. Shares fell 2% to $16.21 in pre-market trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments